Allarity Therapeutics Inc is a clinical-stage, precision medicine company. Allarity Therapeutics Inc is a clinical-stage, precision medicine company.
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib’s...
Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc...
European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the Stenoparib DRP® are also pending in the US, Japan...
Boston (October 10, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.16 | 15.6862745098 | 1.02 | 1.35 | 0.975 | 489517 | 1.03922115 | CS |
4 | 0.18 | 18 | 1 | 1.72 | 0.9405 | 2708108 | 1.07476686 | CS |
12 | -0.25 | -17.4825174825 | 1.43 | 1.72 | 0.9 | 1067086 | 1.08830455 | CS |
26 | -3.464 | -74.5908699397 | 4.644 | 7.38 | 0.9 | 2449714 | 4.14158541 | CS |
52 | -261.02 | -99.5499618612 | 262.2 | 288 | 0.9 | 2876916 | 19.57827021 | CS |
156 | 150049.505977 | -100.000786413 | -150048.325977 | 92640 | -128353.997125 | 1916059 | 1523.32154279 | CS |
260 | 250334.969414 | -100.000471371 | -250333.789414 | 92640 | -167332.373652 | 1863285 | 1361.50056314 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.